Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Impax announced that the Food and Drug Administration (FDA) has approved Pyridostigmine Bromide Extended-Release Tablets, the generic version of Valeant‘s Mestinon Timespan.
RELATED: Canagliflozin Receives Bone Fracture, Density Warning
Mestinon Timespan is a cholinesterase inhibitor indicated for the treatment of myasthenia gravis. It works by inhibiting the destruction of acetylcholine by cholinesterase and thereby permitting freer transmission of nerve impulses across the neuromuscular junction. Pyridostigmine, an analog of neostigmine, is characterized by a longer duration of action and fewer gastrointestinal side effects.
Pyridostigmine Bromide Extended-Release Tablets are available in a 180mg strength.
For more information call (215) 558-4300 or visit ImpaxLabs.com.
